Xylazine awareness, desire, use and exposure: Preliminary findings from the Rhode Island community-based drug checking cohort study.

Autor:	Park JN; Rhode Island Hospital, Providence, RI, United States.; Warren Alpert Medical School, Brown University, Providence, RI, United States., Serafinski R; Rhode Island Hospital, Providence, RI, United States., Ujeneza M; Rhode Island Hospital, Providence, RI, United States., McKenzie M; Rhode Island Hospital, Providence, RI, United States., Tardif J; Rhode Island Hospital, Providence, RI, United States., Krotulski AJ; Center for Forensic Science Research and Education, Fredric Rieders Family Foundation, Horsham, PA, United States., Badea A; Rhode Island Hospital, Providence, RI, United States., Grossman ER; National Institute of Drug Abuse, Bethesda, MD, United States., Green TC; Rhode Island Hospital, Providence, RI, United States.; Warren Alpert Medical School, Brown University, Providence, RI, United States.; Heller School for Social Policy and Management, Brandeis University, United States.
Jazyk:	angličtina
Zdroj:	Drug and alcohol dependence reports [Drug Alcohol Depend Rep] 2024 Jun 05; Vol. 11, pp. 100247. Date of Electronic Publication: 2024 Jun 05 (Print Publication: 2024).
DOI:	10.1016/j.dadr.2024.100247
Abstrakt:	Background: Xylazine is an ⍺2 adrenergic receptor agonist and a veterinary sedative that can cause severe health complications yet interventions to detect and treat human exposure remain underdeveloped. Community-based drug checking services (DCS) involve the testing of small amounts of drugs to increase community knowledge of unregulated supplies and decrease harms. This study characterized xylazine awareness, desire, use and exposure among people who use drugs (PWUD) in Rhode Island, US. Methods: We analyzed data from an ongoing PWUD cohort study. In 2023, 125 PWUD were enrolled and surveyed. Using point-of-care Fourier Transform infrared spectroscopy (FTIR-S), we tested a drug sample from each participant onsite and confirmed the results offsite at a laboratory. Results were conveyed in real-time, along with harm reduction education, referrals to resources and care. Results: Virtually all participants (99.2 %) wanted to avoid xylazine exposure. Half (51.2 %) knew what xylazine was, and a quarter (26.1 %) suspected previous exposure. Xylazine exposure was primarily surmised through sedating (45.2 %) and ulcerative (29.0 %) effects. Only 8.8 % of participants submitted a sample that they expected to contain xylazine. Xylazine was detected in 14.5 % of samples using FTIR-S and in 21.4 % of samples using a dual laboratory approach of gas chromatography mass spectrometry (GC-MS) and liquid chromatography quadrupole-time-of-flight mass spectrometry (LC-QTOF-MS). Participants thought that these xylazine-positive samples were fentanyl (78.3 %), heroin (13.0 %), or Percocet® (8.7 %). Conclusion: Implementing point-of-care DCS at harm reduction organizations could be useful in rapidly increasing xylazine awareness and engaging at-risk individuals in prevention, harm reduction, treatment, and rapid care for xylazine-related wounds. Competing Interests: None. (© 2024 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu